Scholarlink

Background <p>Cancer vaccines offer an innovative approach to treating advanced breast cancer, by activating the immune system to recognize and target cancer cells, aiming to boost immune response, reduce relapse, and enhance patients’ quality of life.</p> Methods <p>A systematic database search was conducted for peer-reviewed, full-text articles on clinical trials focused on cancer vaccines for advanced breast cancer, in the MEDLINE, SCOPUS, Cochrane and ClinicalTrials.gov databases, from conception until October 23, 2024.</p> Results <p>A total of 19 trials, involving 747 patients with advanced breast cancer, were included in this systematic review. Cancer vaccine trials rely primarily on immunological endpoints, with initial small-scale studies showing modest efficacy improvements and highly variable immune response rates (44–100%), suggesting opportunities for further optimization and broader clinical application.</p> Conclusion <p>While the overall quality of the studies was acceptable, heterogeneity in results and limited survival or progression outcomes prevented data synthesis. In conclusion, despite promising findings, the lack of large-scale randomized trials limits definitive conclusions on cancer vaccine efficacy, highlighting the need for Phase III trials to confirm their clinical utility and long-term impact.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A systematic review of the efficacy of cancer vaccines in advanced breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月5日

查看全文
  • Anna Charalampopoulou,
  • Charalampos Filippatos,
  • Panagiotis Malandrakis,
  • Flora Zagouri,
  • Maria Gavriatopoulou,
  • Ioannis Ntanasis-Stathopoulos

摘要

Background

Cancer vaccines offer an innovative approach to treating advanced breast cancer, by activating the immune system to recognize and target cancer cells, aiming to boost immune response, reduce relapse, and enhance patients’ quality of life.

Methods

A systematic database search was conducted for peer-reviewed, full-text articles on clinical trials focused on cancer vaccines for advanced breast cancer, in the MEDLINE, SCOPUS, Cochrane and ClinicalTrials.gov databases, from conception until October 23, 2024.

Results

A total of 19 trials, involving 747 patients with advanced breast cancer, were included in this systematic review. Cancer vaccine trials rely primarily on immunological endpoints, with initial small-scale studies showing modest efficacy improvements and highly variable immune response rates (44–100%), suggesting opportunities for further optimization and broader clinical application.

Conclusion

While the overall quality of the studies was acceptable, heterogeneity in results and limited survival or progression outcomes prevented data synthesis. In conclusion, despite promising findings, the lack of large-scale randomized trials limits definitive conclusions on cancer vaccine efficacy, highlighting the need for Phase III trials to confirm their clinical utility and long-term impact.